5 Most Profitable Pharmaceutical Stocks Now

3. Merck & Co., Inc. (NYSE:MRK)

Trailing Twelve Month Net Income: $14.5 billion

Number of Hedge Fund Holders in Q3 2022: 82

Merck & Co., Inc. (NYSE:MRK) is an American healthcare giant that is a Fortune 500 company and makes and sells products to treat cancer, diabetes, chickenpox, and other diseases.

Merck & Co., Inc. (NYSE:MRK) announced a $1 billion deal in February 2023 through which it will team up with another firm to develop treatments for immune system disorders. Insider Monkey took a look at 920 hedge fund portfolios for last year’s third quarter to determine that 82 had bought the firm’s shares.

Merck & Co., Inc. (NYSE:MRK)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 12 million shares that are worth $1.3 billion.

Follow Merck & Co. Inc. (NYSE:MRK)